Kajinami 2003.

Methods	≥ 8‐Week wash‐out period 24‐Week titration study
Participants	35 Japanese men and women with heterozygous FH; TC > 230 mg/dL (5.94 mmol/L) Exclusion criteria: acute illness, bone disease, chronic endocrine or renal disease, bone metabolism affecting drugs Baseline TC: 9.21 mmol/L (356 mg/dL) Baseline LDL‐C: 7.19 mmol/L (278 mg/dL) Baseline HDL‐C: 1.27 mmol/L (49 mg/dL) Baseline TG: 1.63 mmol/L (144 mg/dL)
Interventions	Atorvastatin 10 mg/d for 0 to 4 weeks Atorvastatin 20 mg/d for 4 to 12 weeks Atorvastatin 40 mg/d for 12 to 24 weeks
Outcomes	Per cent change from baseline at 4 weeks of serum TC, LDL‐C, HDL‐C and TG
Notes	First atorvastatin dose was analysed      SDs were imputed
Risk of bias
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	Atorvastatin 10 mg/d; intervention was analysed, and as no placebo group was included for comparison, assessment of random sequence generation is not applicable
Allocation concealment (selection bias)	Unclear risk	Atorvastatin 10 mg/d; intervention was analysed, and as no placebo group was included for comparison, assessment of allocation concealment is not applicable
Blinding (performance bias and detection bias) All outcomes	Unclear risk	Atorvastatin 10 mg/d; intervention was analysed, and as no placebo group was included for comparison, blinding status is not applicable
Incomplete outcome data (attrition bias) All outcomes	Low risk	Data on all participants were reported
Selective reporting (reporting bias)	Low risk	All lipid parameters were measured
Other bias	Unclear risk	The source of funding was not provided